Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Andrés Cervantes, R. Adam, Susana Roselló et al. · Annals of Oncology · 2022 · 1.6K citations · Full text

Medicine, Oncology, Surgery +14

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

Federico Innocenti, Fang‐Shu Ou, Xueping Qu et al. · Journal of Clinical Oncology · 2019 · 323 citations · Full text

Medicine, Genetics, Oncology +17

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer

Jun Watanabe, Kei Muro, Kohei Shitara et al. · JAMA · 2023 · 258 citations · Full text

Medicine, Oncology, Pharmacology +17

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

Julieta Grasselli, Elena Élez, Ginevra Caratù et al. · Annals of Oncology · 2017 · 194 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study

Chiara Cremolini, Federica Morano, Roberto Moretto et al. · Annals of Oncology · 2017 · 123 citations · Full text

Medicine, Oncology, Metastasis +15